Purdue Pharma Investigated for Opioid Deception

U.S. Attorney's Office is investigating Purdue Pharma's OxyContin as the drugmaker is battling numerous lawsuits regarding its role in the opioid epidemic
Oct. 26, 2017

Purdue Pharma has become the subject of a U.S. investigation related to its painkiller OxyContin as the company fights a number of lawsuits regarding its responsibility for contributing to the country's opioid epidemic, according to a Reuters article.

Stamford, Connecticut-based Purdue said it was cooperating with an investigation by the U.S. Attorney’s Office in Connecticut. “Purdue is committed to being part of the solution to our nation’s opioid crisis and has been cooperating with the U.S. Attorney’s investigation,” Purdue said.

Most lawsuits have accused Purdue of deceptive marketing of OxyContin and convincing doctors and patients that its drugs had a low-risk of addiction and were effective for treating chronic pain.

Read the full story

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates